Cargando…
Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases
Genetic neuromuscular diseases are caused by defective expression of nuclear or mitochondrial genes. Mutant genes may reduce expression of wild-type proteins, and strategies to activate expression of the wild-type proteins might provide therapeutic benefits. Also, a toxic mutant protein may cause ce...
Autor principal: | Verma, Ashok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909143/ https://www.ncbi.nlm.nih.gov/pubmed/29720791 http://dx.doi.org/10.4103/aian.AIAN_298_17 |
Ejemplares similares
-
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017) -
Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases
por: Lin, Mengsi, et al.
Publicado: (2021) -
Antisense Oligonucleotide-Based Therapy of Viral Infections
por: Tarn, Woan-Yuh, et al.
Publicado: (2021) -
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
por: Martinovich, Kelly M., et al.
Publicado: (2018) -
Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)